Seelos Therapeutics Begins Dosing in Phase 1 PK/KD Study

- November 27th, 2019

The company said it expects to announce preliminary data from the Phase 1 cllinical trial in the first quarter of 2020.

Seelos Therapeutics (NASDAQ:SEEL) has announced it has dosed the first patients in its Phase I Pharmacokinetic (PK) and Pharmacodynamic (PD) profile study, SLS-002-102.

As quoted in the press release:

SLS-002-102 is a two-part, randomized, double-blind, placebo-controlled, parallel and crossover study of intranasal and intravenous ketamine which plans to enroll 62 healthy volunteers.

  • 48 subjects in Part A (parallel) will be randomized into four arms to receive either 30mg, 75mg, 90mg of SLS-002 or placebo over 13 days.
  • 14 subjects in Part B (crossover) will be randomized into three arms; 60mg of IV ketamine followed by 60mg SLS-002, 60mg SLS-002 followed by 60mg of IV ketamine, or placebo over 25 days.

“This study should help clarify SLS-002’s safety and tolerability across multiple intranasal doses, as well help to identify and understand any pharmacokinetic or pharmacodynamic differences compared with IV ketamine. This information will assist us in confirming the dosing strategy for the planned proof of concept study in patients with MDD suffering from ASIB,” said Raj Mehra, Ph.D., Chairman and CEO of Seelos Therapeutics.

Preliminary data from this study is expected in the first quarter of 2020.

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply

Your email address will not be published. Required fields are marked *